Clinical Trials Directory

Trials / Terminated

TerminatedNCT03716258

Characterizing Biomarkers of Early Parkinson's Disease Progression (TREG)

Characterizing Biomarkers of Early Parkinson's Disease Progression

Status
Terminated
Phase
Study type
Observational
Enrollment
16 (actual)
Sponsor
Oregon Health and Science University · Academic / Other
Sex
All
Age
40 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to look at a blood marker of inflammation in early untreated Parkinson's disease.

Detailed description

Objectives: Parkinson's disease is the second most common neurodegenerative condition worldwide, and while both motor and non-motor symptoms can be improved with symptomatic therapies, there are currently no drugs that slow or halt progression of the disease. All previous trials of neuroprotective therapies have failed, in large part due to the lack of objective, sensitive biomarkers of Parkinson's disease progression. Plan: The proposed study aims to characterize the rate of change in a peripheral blood marker of inflammation (Treg percentage) and three quantitative motor measures (finger tapping, 9-hole peg test and peak turn velocity) in a cohort of 25 untreated PD patients with motor testing and blood sampling performed at baseline and at 6 months Methods: Participants will have three visits to the Portland VA over a 12 month period. Assessments will be made regarding their Parkinson's disease progression (motor ability and gait and balance). At each visit, a VA phlebotomist will draw whole blood. The VA lab will analyze whole blood for metabolic CBC with differential. The research team will hand carry blood samples from the VA phlebotomist to Dr. Quinn's VA lab in BLDG 103 - E143. A plasma sample will be added to the Neurologic Disorders Repository (MIRB # 3129). Peripheral blood mononuclear cells (PBMC) will be isolated from buffy coats using Ficoll-Paque. The PBMC will be frozen and batch analyzed for T lymphocytes using flow cytometry at OHSU.

Conditions

Timeline

Start date
2019-01-01
Primary completion
2021-05-01
Completion
2021-05-01
First posted
2018-10-23
Last updated
2022-04-20

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT03716258. Inclusion in this directory is not an endorsement.